CLSA technical analyst Laurence Balanco has flagged Dixon Technologies as a key buy candidate following a 20% correction over the last six months. According to reports from CLSA, Balanco's recommendation comes after the stock built a base between January and May 2026, largely trading rangebound during this period. Since the turn of the year, Dixon Tech has depreciated around 3%, compared to the 22% drawdown in the past 12 months, as reported by CLSA.
Balanco believes the NSE Midcap Index is on the cusp of a major breakout from a consolidation pattern that has been forming since 2024. As reported by CLSA, if confirmed, this breakout would support an upside target of 77,687 to 78,000. The potential breakout in midcaps while the Nifty remains range-bound suggests a broadening of market participation and a rotation into the mid-tier of the market, which historically tends to be bullish for risk appetite.
According to CLSA analysis, the Nifty 50 remains range-bound within its 2024-to-date trading range, defined by the 21,743-21,800 support zone on the downside and 26,270-26,340 resistance on the upside. While the headline index stays anchored in this range, the more interesting setup is in the midcap space, as noted by Balanco in his latest price action note.
Motilal Oswal has reiterated its 'Buy' rating on Zensar Technologies Ltd., with a target price of ₹640, implying a 31% upside from the current market price of ₹488. The brokerage remains constructive on the mid-tier IT firm, citing improving deal momentum, a differentiated AI strategy, and strong medium-term growth visibility supported by a large deal win. With banking, financial services and insurance and manufacturing providing a relatively resilient base, this shall help Zensar achieve better growth.
Jefferies has maintained its 'buy' rating on Entero Healthcare Solutions Ltd., raising the target price to ₹1,500 from ₹1,350. The current market price stands at ₹1,280, implying an 17.18% upside. According to Jefferies, Entero reported strong Q4 performance with revenue of ₹19.1 billion, up 43% YoY and 12% QoQ, which was 6% above estimates. The Ebitda came in at ₹0.9 billion, up 76% YoY and 27% QoQ, which was 15% above estimates. The organic growth for the quarter stood at around 17% YoY, with management providing a robust FY27 outlook indicating revenue growth of 23%.
